Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 8Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Colorectal Neoplasms 7Prostatic Neoplasms 6Urinary Bladder Neoplasms 5Leukemia, Myeloid, Acute 5Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Lung Neoplasms 4Glioblastoma 4Triple Negative Breast Neoplasms 3Mouth Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Ureteral Neoplasms 2Stomatitis 2Recurrence 2Oropharyngeal Neoplasms 2Melanoma 2Laryngeal Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2COVID-19 2Brain Neoplasms 2Adenocarcinoma 2

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bilateral Breast Carcinoma × Standard of Care × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡